Target intelligence / Profile preview

Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1)

Target
NLRX1
Molecular classification
Pattern recognition receptor, NOD-like receptor, Regulatory nucleoside triphosphatase, Intracellular receptor, ATPase
01

Overview

NLRX1 (Nucleotide-binding oligomerization domain, leucine rich repeat containing X1) is an intracellular NOD-like pattern recognition receptor distinct from other inflammasome-associated NLR proteins. It inhibits pro-inflammatory pathways, including NF-κB and type-I interferon signaling, and is involved in negative regulation of innate immune responses, ROS production, autophagy, and cell death. NLRX1 functions as a key modulator of inflammation and immune signaling through scaffolding of multiprotein complexes but does not form canonical inflammasomes. Altered expression or function of NLRX1 is linked to susceptibility and severity of various inflammatory and infectious diseases, making it an emerging target for immunomodulatory drug discovery[1][2][3][6].

Other names
NOD-like receptor X1NLR family, X1NOD5NOD9CLR11.3
02

Mechanism of action

Allosteric modulation of oligomerization and catalytic ATP binding, Modulation of signaling protein–protein interactions, Negative regulation of antiviral and inflammatory signaling pathways

03

Biological functions

Negative regulation of innate immune signalingRegulation of inflammationNegative regulation of NF-κB and type-I interferon (IFN-I) pathwaysModulation of reactive oxygen species (ROS) productionRegulation of autophagyRegulation of cell deathScaffolding for multiprotein complex formation
04

Disease associations

InflammationInfectious diseasePotential roles in cancer and autoimmune disorders
05

Safety considerations

Targeting immunoregulatory proteins could risk undesired immunosuppression or enhanced susceptibility to infection; thorough safety evaluation is required for therapeutics targeting NLRX1
06

Interacting drugs

In development—small molecule activators (no clinically approved drugs as of current data)
07

Biomarkers

Altered NLRX1 expression can associate with inflammation and may have potential as a biomarker for inflammatory disease states

Beyond the preview

Go deeper on Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call